Omeros Corporation (FRA:3O8)
Germany
· Delayed Price · Currency is EUR 9.23
-0.14 (-1.55%)
At close: Dec 5, 2025
Omeros Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
202
Market Cap
661.26M EUR
Revenue Chart
* This company reports financials in USD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SAP SE | 36.49B |
| Siemens Aktiengesellschaft | 78.91B |
| Allianz SE | 105.02B |
| Deutsche Telekom AG | 121.02B |
| Siemens Energy AG | 39.08B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Rheinmetall AG | 11.00B |
| Deutsche Bank Aktiengesellschaft | 29.86B |
Omeros News
- 4 days ago - Omeros (OMER) Receives Consistent 'Buy' Rating from D. Boral Capital | OMER Stock News - GuruFocus
- 4 days ago - Omeros (OMER) Secures $2.1B Deal with Novo Nordisk - GuruFocus
- 4 days ago - Omeros, Novo Nordisk close up to $2.1B deal for phase 2 asset zaltenibart - Seeking Alpha
- 4 days ago - Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906) - Wallstreet:Online
- 4 days ago - Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906) - Business Wire
- 14 days ago - Omeros: Key Milestone Ahead, Risk-Averse Investors Should Avoid - Seeking Alpha
- 18 days ago - Omeros Corporation (OMER) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 18 days ago - Omeros (OMER) Q3 2025 Earnings Call Transcript - The Motley Fool